Major Depressive Disorder

AXS-05 also showed superiority to placebo in safety.

With administration strategies for the psychiatric anesthetic drug well established, clinicians have interest in accumulating long-term data and other potential indications.

The lead author of treatment recommendations weighs in on their current use and future research.

New phase 3 data presented at APA 2022 support the agent as an adjunctive in older patients without benefit from monotherapy antidepressant medication.

Anita Clayton, MD, reviews the available phase 2 and 3 clinical data for the novel, once-daily oral investigative drug.

Dr. Carolyn Rowley talks about the Cayenne Wellness Center's mental health initiative for individuals with sickle cell disease and shares the story of one of her first patients.

The first controlled trial of the combination therapy shows its benefit in 6-week depressive symptom improvement versus lone bupropion.

At Pri-Med West, primary care providers ask Dr. Michael Ziffra and Dr. Shirah Vollmer all the questions they have about treating mental illness and prescribing different classes of drugs.

Dr. Shirah Vollmer and Dr. Michael Ziffra host a Question & Answer Session addressing common inquiries about mental health treatment in the primary care setting.

Dr. Levine is joined by Dr. Sanjay Mathew to talk about some exciting treatments in the pipeline for psychiatric disorders.

There were key aspects that differed in the gut microbiota between patients with major depressive disorder and the healthy control group.

Patients with inflammatory bowel disease are at an increased risk of developing depression.

The digital software program was significantly beneficial and tolerable among patients who used it over 6 weeks, according to new findings.

Dave Bellevue of The Oxymorrons joins Steve to talk about his journey to mental health advocacy.

There is a need for new medications for depression to overcome high rates of treatment resistance.

Subhdeep Virk, MBBS, chaired the recent State of the Science event on treatment-resistant depression.

Patients who screened positive for depression had worse dry eye symptoms and overall signs but similar inflammatory markers compared to those negative for depression.

In the first episode of Rethinking Psychiatry, Dr. Steve Levine is joined by Dr. Gul Dolen for a discussion on how the brain shapes social behavior.

Virk will chair a discussion on depression treatments on March 3.

The Supplemental New Drug Application was based on the results of numerous clinical trials.

Sage Therapeutics and Biogen expect to apply to the FDA in 2022.

The number of dropouts and dropouts because of adverse events did not differ between treatments.

A 3-part series on the manifestations of physician burnout, how COVID-19 changed its scope and revealed systemic fractures, and finally, the path towards resolution and reformation.

Our third and final episode on physician burnout traces the path towards a solution and ultimately, reformation in the system as a whole.